Author:
Levy-Mendelovich Sarina,Atia Nitzan,Budnik Ivan,Barg Assaf Arie,Avishai Einat,Cohen Omri,Brutman-Barazani Tami,Livnat Tami,Kenet Gili
Reference39 articles.
1. Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project;Manco-Johnson;Blood,2017
2. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres;Soucie;Haemophilia,2020
3. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 Study;Schmitt;Thromb Haemost,2020
4. Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the phase IIIb STASEY study [abstract];Kiialainen;Res Pract Thromb Haemost,2020
5. Prophylaxis in children with haemophilia in an evolving treatment landscape;Mancuso;Haemophilia,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献